蛋白酶激活受体-2和脂代谢分析在高尿血症诱导的脏损伤
Xiaolu Sui1, Tingfei Xie2, Yunpeng Xu1
1Department of Nephrology, The Second Affiliated Hospital of Shenzhen University, Shenzhen 518000, Guangdong, China.
Mediators of inflammation
|July 24, 2023
概括
蛋白酶激活受体-2 (PAR2) 在高尿血症中驱动脏炎症. 用AZ3451阻断PAR2可减少炎症和损伤,为与高尿血症相关的损伤提供潜在的治疗方法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 炎症研究 炎症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 间歇性炎症是与高尿血症相关的损伤的关键因素.
- 蛋白酶激活受体-2 (PAR2) 与炎症性疾病有关,并且在PI3K/AKT/NF-κB通路上游起作用.
研究的目的:
- 为了研究PAR2在高尿血引起的损伤中的作用.
- 评估PAR2抗剂 (AZ3451) 在超尿血症大鼠模型中的治疗潜力.
主要方法:
- 通过使用腺素和乙醇树脂,建立了超尿血病大鼠模型.
- 在组织中分析了PAR2和PI3K/AKT/NF-κB通路表达.
- 评估了PAR2抗剂AZ3451对损伤,炎症和脂代谢的影响.
主要成果:
- 超尿血症显著上调PAR2和PI3K/AKT/NF-κB通路的表达,导致炎症细胞透和脏组织损伤.
- AZ3451治疗抑制了PAR2和PI3K/AKT/NF-κB通路,减少了管道扩张和炎症.
- 在正常和高尿素性大鼠之间观察到不同的脂代谢概况,而AZ3451影响了这些概况.
结论:
- 通过激活PI3K/AKT/NF-κB通路,PAR2激活有助于高尿血中介性损伤.
- 与AZ3451的PAR2对抗性表明,在高尿血引起的损伤中减轻炎症反应的治疗有希望.
相关概念视频
01:24Phase II Reactions: Glucuronidation
526
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
526
01:29Acute Kidney Injury II: Pathophysiology
34
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
34
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:28Renal Drug Excretion: Tubular Secretion
224
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
224
01:14Drug Metabolism: Phase II Reactions
3.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
15
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
15